id: NEW:genetic_variants_opioid_response_to_sud_medication_treatment_rate_oud
name: Genetic Variants Associated with Opioid Response â†’ OUD Medication Treatment Rate
from_node:
  node_id: NEW:genetic_variants_opioid_response
  node_name: Genetic Variants Associated with Opioid Response
to_node:
  node_id: sud_medication_treatment_rate_oud
  node_name: OUD Medication Treatment Rate
direction: positive
category: biological
mechanism_pathway:
- 'Step 1: Genetic variants in opioid-related pathways influence individual pharmacokinetic and pharmacodynamic
  responses to buprenorphine'
- 'Step 2: These variants affect mu-opioid receptor binding affinity and downstream signaling cascades'
- 'Step 3: Differential biological responses manifest as variable treatment outcomes measured by urine
  drug screen results'
- 'Step 4: Identification of predictive genetic markers could enable personalized treatment approaches
  to improve response rates'
evidence:
  quality_rating: B
  n_studies: 3
  primary_citation: Christal N Davis et al. 2025. "Multi-ancestry genome-wide association meta-analysis
    of buprenorphine treatment response.." https://doi.org/10.1038/s41386-025-02117-z
  supporting_citations:
  - VA Million Veteran Program cohort studies on opioid use disorder treatment
  - Extended-release buprenorphine clinical trial referenced in the study (n=296)
  - Additional citations require full-text access for complete bibliography
  doi: 10.1038/s41386-025-02117-z
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Genome-wide association meta-analysis investigating genetic predictors of buprenorphine treatment
  response in patients with opioid use disorder, using urine drug screen results as the outcome measure
  across multiple ancestral populations.
quantitative_effects:
  sample_size: 4690
moderators:
- name: Ancestry/Population background
  direction: strengthens
  strength: moderate
  description: Multi-ancestry design enables detection of both shared and population-specific genetic
    signals affecting treatment response
structural_competency:
  equity_implications: 'While this study focuses on biological/genetic factors, structural implications
    include: (1) inequitable access to precision medicine approaches across populations, (2) historical
    underrepresentation of non-European ancestries in pharmacogenomic research contributing to treatment
    disparities, (3) the need for equitable research inclusion to ensure genetic findings benefit all
    populations. The multi-ancestry design represents a structural improvement in research equity.'
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:36.898344'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
